OCC: Respiratory Virus Panel Nucleic Acid Assay System

Product code OCC, “Respiratory Virus Panel Nucleic Acid Assay System” in FDA's classification database, is a Class II device type under 21 CFR 866.3980 (respiratory viral panel multiplex nucleic acid assay), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 80 clearances under OCC, 68 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
OCC
Regulation
21 CFR 866.3980
Class
II
Panel
Microbiology
Clearances
80
Most recent
Aug 31, 2026
Median review, last 2 years
79 days
Third-party review
Not eligible
Implant
No

What it covers

A respiratory viral panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple viral nucleic acids extracted from human respiratory specimens or viral culture. The detection and identification of a specific viral nucleic acid from individuals exhibiting signs and symptoms of respiratory infection aids in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory findings. The device is intended for detection and identification of a combination of the following viruses: Influenza A and Influenza B, Influenza A subtype H1 and Influenza A subtype H3, Respiratory Syncytial Virus subtype A and Respiratory Syncytial Virus subtype B, Parainfluenza 1, Parainfluenza 2, and Parainfluenza 3 virus, Human Metapneumovirus, Rhinovirus, and Adenovirus.

FDA’s definition of product code OCC, from the Product Classification database.

Recent clearances

510(k)DeviceApplicantDecisionType
K262747ID NOW Influenza A & B 2; ID NOW RSV; ID NOW Strep A 2; ID NOW COVID-19 2.0Abbott Diagnostics Scarborough, Inc.Aug 31, 2026Special
K254139BioCode® Respiratory Pathogen Panel (RPP)Applied BioCode, Inc.May 1, 2026Traditional
K242613NxTAG® Respiratory Pathogen PanelLuminex Molecular Diagnostics, Inc.Oct 2, 2024Special
K232775ID NOW Influenza A & B 2Abbott Diagnostics Scarborough, Inc.Oct 10, 2023Special
K231017Panther Fusion AdV/hMPV/RV AssayHologic, Inc.May 5, 2023Special
K213822cobas Influenza A/B & RSV nucleic acid test for use on the cobas Liat SystemRoche Molecular Systems, Inc.Jul 6, 2022Special
K210234cobas Influenza A/B & RSV Nucleic acid test for use on the cobas Liat SystemRoche Molecular Systems, Inc.Feb 16, 2021Special
K201505Simplexa Flu A/B & RSV Direct Gen II, Simplexa Flu A/B & RSV Positive Control PackDiasorin Molecular, LLCAug 22, 2020Traditional
K200065cobas Influenza A/B Nucleic acid test for use on the cobas Liat System, cobas Influenza A/B & RSV Nucleic acid test for use on the cobas Liat System, cobas Strep A Nucleic acid test for use on the cobas Liat SystemRoche Molecular Systems, Inc.Feb 10, 2020Special
K192485BioCode Respiratory Pathogen Panel (RPP)Applied BioCode, Inc.Dec 23, 2019Traditional
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 80 with a free account)

Clearances by year

68 OCC 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)279
2024129
2023227
20221210
2021119
2020253
2019531
20184134
201710136
2016792
2015885
2014494
2013679
20126125
2011982

Who submits

29 applicants cleared a OCC device since 2011. 87% of the clearances went to applicants in United States, then Canada (9%), Belgium (1%) and Germany (1%). By type: Traditional 63%, Special 28% and Dual Track 9%.

ApplicantClearances since 2011
Cepheid8
Luminex Molecular Diagnostics, Inc.6
Alere Scarborough, Inc.5
Biofire Diagnostics, LLC4
Hologic, Inc.4
Roche Molecular Systems, Inc.4
Abbott Diagnostics Scarborough, Inc.3
Gen-Probe Prodesse, Inc.3

How FDA classifies it

Class II (special controls). The special controls are:

(1) FDA's guidance document entitled “Class II Special Controls Guidance Document: Respiratory Viral Panel Multiplex Nucleic Acid Assay;”

(2) For a device that detects and identifies Human Metapneumovirus, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Human Metapneumovirus (hMPV) Using Nucleic Acid Assays;” and

(3) For a device that detects and differentiates Influenza A subtype H1 and subtype H3, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Detection and Differentiation of Influenza A Virus Subtypes Using Multiplex Nucleic Acid Assays.” See § 866.1(e) for the availability of these guidance documents.

From 21 CFR 866.3980. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 866.3980 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent OCC clearances declared.

Ask about OCC

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about OCC

What is FDA product code OCC?

Product code OCC, “Respiratory Virus Panel Nucleic Acid Assay System” in FDA's classification database, is a Class II device type under 21 CFR 866.3980 (respiratory viral panel multiplex nucleic acid assay), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 80 clearances under OCC, 68 of them since 2011.

How many 510(k) clearances are there under OCC?

FDA’s 510(k) database listed 80 clearances under OCC as of Oct 29, 2026, 68 of them decided since 2011; the most recent decision was Aug 31, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a OCC 510(k)?

For the 2 OCC clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 79 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most OCC clearances?

Since 2011: Cepheid (8), Luminex Molecular Diagnostics, Inc. (6), Alere Scarborough, Inc. (5), Biofire Diagnostics, LLC (4) and Hologic, Inc. (4). 29 applicants have cleared a OCC device in that time.

Sources

  1. FDA product classification: OCC · Product Classification database
  2. 21 CFR 866.3980: Respiratory viral panel multiplex nucleic acid assay · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for OCC · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow OCCGet an email when FDA clears, recalls or publishes guidance for OCC devices.

Know what FDA already cleared.